- Home
- CARM vs BOLT Comparison
CARM vs BOLT Comparison
Compare CARM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- BOLT
- Stock Information
- Founded
- CARM 2016
- BOLT 2015
- Country
- CARM United States
- BOLT United States
- Employees
- CARM N/A
- BOLT N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- BOLT Health Care
- Exchange
- CARM Nasdaq
- BOLT Nasdaq
- Market Cap
- CARM 19.7M
- BOLT 22.6M
- IPO Year
- CARM N/A
- BOLT 2021
- Fundamental
- Price
- CARM $0.45
- BOLT $0.49
- Analyst Decision
- CARM Hold
- BOLT Hold
- Analyst Count
- CARM 5
- BOLT 5
- Target Price
- CARM $4.57
- BOLT $1.25
- AVG Volume (30 Days)
- CARM 512.7K
- BOLT 113.0K
- Earning Date
- CARM 03-31-2025
- BOLT 03-20-2025
- Dividend Yield
- CARM N/A
- BOLT N/A
- EPS Growth
- CARM N/A
- BOLT N/A
- EPS
- CARM N/A
- BOLT N/A
- Revenue
- CARM $20,268,000.00
- BOLT $9,779,000.00
- Revenue This Year
- CARM $46.34
- BOLT $9.87
- Revenue Next Year
- CARM N/A
- BOLT N/A
- P/E Ratio
- CARM N/A
- BOLT N/A
- Revenue Growth
- CARM 41.13
- BOLT 35.86
- 52 Week Low
- CARM $0.38
- BOLT $0.46
- 52 Week High
- CARM $2.77
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- CARM 44.17
- BOLT 45.52
- Support Level
- CARM $0.43
- BOLT $0.48
- Resistance Level
- CARM $0.50
- BOLT $0.52
- Average True Range (ATR)
- CARM 0.05
- BOLT 0.03
- MACD
- CARM 0.00
- BOLT 0.00
- Stochastic Oscillator
- CARM 28.16
- BOLT 40.32
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.